Track market-moving stories before they get noisy

Paramount Skydance Corporation is rated Buy with a $12.32 12-month price target, driven by operational inflection and merger potential. Q1 adjusted EBITDA surged 59% on just 2% revenue growth, highlighting emerging operating leverage and cost discipline across PSKY's diversified media assets. Streaming momentum is accelerating, with Paramount+ reaching 79.6 million subscribers and platform unification expected to further boost engagement and margins.

Paramount Skydance CEO David Ellison has prioritized putting streaming services on one tech platform. Jonathan Raa/NurPhoto via Reuters Connect; Valerie Macon / AFP via Getty Images; Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images Paramount Skydance is preparing to move around some streaming staffers as David Ellison's company wraps up its long-term project of unifying the tech platforms of Paramount+ and free streamer Pluto TV.

This so-called "convergence" project has been a top priority for Paramount. Two high-level streaming employees recently said that convergence is on pace to meet the company's stated goal of a "mid-year launch." While Paramount is planning to keep Paramount+ and Pluto TV as separate services, the hope is that having a single tech platform will save resources and improve recommendations across each app, which could drive higher engagement.

Once convergence is complete, Paramount is planning to reassign staffers who've worked on it, streaming leaders told employees during a quarterly meeting on Wednesday morning.

Paramount said it will "organize our teams against thematic pillars" like monetization, content, and live & video, according to a screenshot of the presentation viewed by Business Insider.

Streaming staffers also learned that some employees "will be utilized to create select additional Solutions Teams" focused on advertising formats, user experience for the short-form video feed on Paramount+, and video playback.

A person familiar with Paramount's streaming strategy said these changes are about "redeploying" product employees after convergence is finished. They said most streaming staff won't be affected by these changes and that no associated layoffs were planned.

Boosting tech beyond convergenceSince Ellison became Paramount's CEO in August, the company has prioritized technology by shaking up teams, making key hires, and adding new streaming features.

Paramount merged some technical streaming teams in March, Business Insider reported. The company said that putting the Paramount+ Global Quality Engineering group and Pluto TV's Software Test Engineering team under one roof helped facilitate "AI enablement and automated testing."

Ellison's company has also emphasized data by expanding the role of EVP Jason Kim, who, since January, has overseen data and insights across all of Paramount, not just streaming.

Paramount has made several key hires. They include former Google AI executive Barak Turovsky as head of consumer AI; fellow former Google executive Hugh Williams as an EVP; and former Amazon ad sales leader Danielle Carney as head of its US ad sales group. Ellison has also brought over product chief Dane Glasgow from Meta and revenue chief Jay Askinasi from Roku.

Paramount has had key departures as well, including former tech chief Phil Wiser in May and former head of streaming product and tech Vibol Hou in January.

Besides marrying the tech stacks of Paramount+ and Pluto TV, Paramount hopes to boost streaming engagement by adding vertical video clips and interactive features, such as a shopping tool. The company is exploring adding video podcasts; rival Netflix recently made a major move into licensed podcasts.

Paramount's most transformative change would be buying Warner Bros. Discovery, which would give it control of the Warner Bros. Studio, HBO, HBO Max, and cable networks like CNN. The merger still needs regulatory approval in the US and abroad, which the company hopes to get by the end of September.

Read next

James Faris You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Media Exclusive

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the launch of its “LG-UTUC Luminaries” initiative, recognizing clinicians and institutions demonstrating leadership, expertise, and a commitment to advancing low‑grade upper tract urothelial cancer (LG‑UTUC) care.

LG‑UTUC is a rare form of cancer affecting an estimated 6,000-7,000 patients each year in the U.S., which represents approximately 40% of patients diagnosed in the U.S. annually with UTUC. While typically noninvasive, it often recurs and may require repeated endoscopic procedures or radical surgery to remove the kidney and ureter, underscoring a continued need for guideline-recommended kidney‑sparing care approaches.

“Through the LG-UTUC Luminaries initiative, we are honored to recognize the clinicians and institutions redefining what is possible for patients living with LG-UTUC,” said Liz Barrett, President and Chief Executive Officer of UroGen. “By elevating these leaders, we aim to inspire broader adoption of evidence-based, kidney-sparing care, strengthen collaboration across the urology community, and accelerate progress toward a future where patients with this highly recurrent disease have better outcomes and a better care experience.”

The LG-UTUC Luminaries initiative recognizes clinicians and institutions working to achieve excellence in LG-UTUC care. Honorees have extensive experience with LG-UTUC and are actively involved in treatment, research, and peer-to-peer education. Institutional recipients are distinguished by established, guideline-aligned care pathways spanning diagnosis, treatment, and long-term surveillance, as well as strong commitments to physician training, research participation, and comprehensive patient support.

UroGen recognizes Saum Ghodoussipour, MD, Director, Bladder and Urothelial Cancer Program, Rutgers Cancer Institute, and Associate Professor of Surgery, Rutgers Robert Wood Johnson Medical School, as the first recipient of this flagship LG-UTUC Luminaries recognition—an honor that will continue to be presented to physicians and institutions dedicated to helping shape the future of kidney-sparing management in LG-UTUC.

“I’m truly honored to receive this recognition,” said Dr. Saum Ghodoussipour, Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, NJ. “This distinction reflects the dedication of our entire multidisciplinary team at Rutgers Cancer Institute, whose commitment to advancing education, research, and patient-centered care continues to drive progress for individuals living with LG-UTUC. I’d especially like to recognize Dr. Vignesh Packiam, Director of Clinical and Translational Research in Urologic Oncology and Associate Professor of Surgery at Rutgers Robert Wood Johnson Medical School, whose leadership and contributions have been instrumental in shaping our program. Together, we remain committed to improving outcomes through collaboration, innovation, and a steadfast focus on our patients.”

About the LG-UTUC Luminaries Initiative
The LG-UTUC Luminaries initiative is UroGen’s effort to recognize and collaborate with leading clinicians and institutions advancing care for patients with low-grade upper tract urothelial cancer. By highlighting clinical leadership and fostering collaboration across the urology community, the initiative supports continued progress in kidney-sparing care and efforts to improve outcomes in this rare and highly recurrent disease.

About UroGen Pharma Ltd. 
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

INVESTOR CONTACT:
Vincent Perrone
[email protected]
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
[email protected]
(609) 460-3566 Ext. 1083

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7%Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17th at 8:30 AM ETConference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent developments.

“2026 is off to a strong start, with expanding usage of ZUSDURI™ (mitomycin) for intravesical solution and clear acceleration across key commercial indicators, including prescriber trial and adoption,” said Liz Barrett, President and Chief Executive Officer of UroGen. “These trends reflect growing clinical confidence in ZUSDURI as a primary, non-surgical therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The early launch momentum is now translating into meaningful revenue growth, providing early validation of our commercial model and reinforcing the blockbuster potential for ZUSDURI. In parallel, we continue to advance our broader pipeline, including next generation products UGN-103 in LG-IR-NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma (LG-UTUC), as well as UGN-501, our investigational, potentially best-in-class, next-generation oncolytic virus. With this momentum, we are well positioned to execute our long-term growth strategy and continue to expand our leadership position in uro-oncology.”

Q1 2026 and Recent Business Highlights:

ZUSDURI (mitomycin) for intravesical solution:

Commercial launch of ZUSDURI continues to accelerate, following its U.S. FDA-approval as the first and only FDA-approved medicine for adults with recurrent LG-IR-NMIBC.The permanent Healthcare Common Procedure Coding System Level II J Code (J9282) became effective on January 1, 2026 and has enabled broader adoption by improving reimbursement clarity and confidence across both hospital and community settings.ZUSDURI achieved net product revenue of $29.2 million in the first quarter of 2026, representing 109% quarter-over-quarter growth. The accelerating growth trend in prescribers, particularly repeat prescribers, reflects increasing health care provider confidence and successful integration of ZUSDURI into routine urology practice. As of March 31, 2026, UroGen reported: 972 activated sites of care256 unique ZUSDURI prescribers103 repeat ZUSDURI prescribers Updated results from the Phase 3 ENVISION trial evaluating ZUSDURI were published online ahead of print in the Journal of Urology. The publication reported that patients who achieved a complete response (CR) three months after the first instillation of ZUSDURI had a 72.2% probability of remaining event-free 24 months after CR (95% CI: 64.1%, 78.8%) as determined by Kaplan-Meier analysis.
JELMYTO (mitomycin) for pyelocalyceal solution in LG-UTUC:

Generated net product revenue of $21.7 million in the quarter ended March 31, 2026, an increase of approximately 7% over the $20.3 million reported for first quarter of 2025.
Next-generation novel mitomycin-based formulations for urothelial cancer

UroGen plans to submit a New Drug Application (NDA) for UGN-103 (mitomycin) for recurrent LG-IR-NMIBC in the second half of 2026 with potential FDA approval in 2027. The FDA has agreed with the Company’s regulatory plan to submit the NDA based on the data from the Phase 3 UTOPIA trial. Top line results from UTOPIA were reported in November 2025, demonstrating a 77.8% three-month CR rate (95% CI, 68.3%, 85.5%). For more information on the UTOPIA trial, refer to clinicaltrials.gov/NCT06331299.UGN-103 is a next-generation mitomycin product designed to offer improvements over ZUSDURI, including a shorter manufacturing process and simplified reconstitution procedure. It combines UroGen’s RTGel® technology with a novel mitomycin formulation licensed from medac. UroGen continues to evaluate lifecycle management and pipeline expansion opportunities, including potential applications in high-grade NMIBC settings and adjuvant use of UGN-103 in IR-NMIBC patients.The Phase 3 clinical trial to explore the safety and efficacy of UGN-104 is ongoing and is expected to be fully enrolled by the end of 2026. UGN-104 is a next-generation mitomycin product for LG-UTUC. For more information on the UGN-104 Phase 3 trial (UT002), refer to https://clinicaltrials.gov/study/NCT06774131.
UGN-501 (investigational next-gen oncolytic virus) for use in high-grade non-muscle invasive bladder cancer

UGN-501 is a potent and fast-replicating investigational next-generation oncolytic virus being developed as a locally administered cancer treatment. Investigational New Drug (IND)-enabling studies are nearing completion, and UroGen plans to submit an IND in the second quarter of 2026 and initiate a Phase 1 clinical trial in NMIBC by year end. Nonclinical data to date demonstrate cytotoxic activity across a panel of bladder cancer cell lines representing a broad range of tumor stages and grades. The Phase 1 trial will initially evaluate aqueous intravesical administration of UGN-501, and UroGen plans to evaluate delivery using its proprietary RTGel technology, which may enable prolonged dwell time and enhanced local activity. The initial focus is bladder cancer with the potential to expand into additional tumor types beyond the genitourinary system.
Expanded Debt Facility with Pharmakon Advisors

In February 2026, UroGen entered into an amended and restated loan agreement with Pharmakon Advisors for two additional tranches of senior secured term loans. The first tranche of $200 million was funded at closing to refinance the existing $125 million loan facility and provide additional non-dilutive capital. A second tranche of $50 million may be drawn at the Company's option no later than June 30, 2027, subject to customary conditions. All outstanding loans with Pharmakon Advisors will accrue interest at a fixed rate of 8.25% and be repaid in four equal quarterly payments commencing in the second quarter of 2030. All outstanding loans with Pharmakon Advisors can be prepaid in whole at UroGen's discretion at any time, subject to prepayment premiums, make-whole amounts, as applicable, and fees.
American Urological Association Key Opinion Leader Panel to Showcase Real-World Experience with ZUSDURI

UroGen will host a KOL panel at the upcoming AUA Annual Meeting focused on real-world experience with ZUSDURI, including patient selection, workflow integration, treatment patterns, and patient outcomes. The event will feature leading urologists highlighting the role of ZUSDURI as a primary, non-surgical treatment option in recurrent low-grade intermediate-risk NMIBC and will be webcast and accessible through the Company’s website. To register click here.
First quarter 2026 Financial Results

Revenue: Total revenue was $51.0 million in the first quarter ended March 31, 2026, compared with $20.3 million in the first quarter of 2025. Year-over-year revenue growth of 152% was primarily driven by the commercial launch of ZUSDURI and JELMYTO revenue growth.

Research and Development (R&D) Expenses: R&D expenses were $15.6 million in the first quarter of 2026, including non-cash share-based compensation expense of $0.8 million. This compares to $19.9 million, including non-cash share-based compensation expense of $0.6 million, for the same period in 2025. The decrease in R&D expenses was primarily attributable to the acquisition of UGN-501 in the first quarter of 2025 and ZUSDURI manufacturing costs, which were recognized as R&D expense in the first quarter of 2025 prior to receiving FDA approval.

Selling, General and Administrative (SG&A) Expenses: SG&A expenses were $51.5 million in the first quarter of 2026, including non-cash share-based compensation expense of $3.9 million. This compares to $35.0 million, including non-cash share-based compensation expense of $2.5 million, for the same period in 2025. The increase in SG&A expenses was primarily attributable to ZUSDURI commercial activities, including the sales force expansion following ZUSDURI approval and higher brand marketing expenses, an increase in overall commercial operation costs, and higher advisory costs, including fees associated with the Pharmakon Advisors debt refinancing in the first quarter of 2026.

Financing on Prepaid Forward Obligation: UroGen reported non-cash financing expense related to the prepaid forward obligation to RTW Investments of $4.5 million in the first quarter of 2026 compared with $4.6 million in the same period in 2025.

Interest Expense on Long-term Debt: Interest expense related to long-term debt was $4.2 million in the first quarter of 2026, compared to $4.1 million in the same period in 2025. The increase in interest expense was primarily attributable to the additional borrowings of $75.0 million in the first quarter of 2026 in connection with the Pharmakon refinancing of long-term debt, offset by the lower interest rate.

Net Loss: UroGen reported a net loss of $23.6 million or ($0.47) per basic and diluted share in the quarter ended March 31, 2026, compared with a net loss of $43.8 million or ($0.92) per basic and diluted share in the first quarter of 2025.

Cash, Cash Equivalents and Marketable Securities: As of March 31, 2026, cash, cash equivalents and marketable securities totaled $140.3 million.

2026 JELMYTO Revenue and Company Operating Expense Guidance: The Company continues to expect 2026 net product revenue for JELMYTO to be in the range of $97 million to $101 million. This implies a year-over-year growth rate of approximately 3% to 7% over the $94 million of JELMYTO revenue reported in 2025. The Company is not providing full-year 2026 revenue guidance for ZUSDURI at this time, as the product remains in the early stages of its commercial launch. The Company continues to expect full-year 2026 operating expenses to be in the range of $240 million to $250 million, including non-cash share-based compensation expense of $20 million to $24 million.

Conference Call & Webcast Information: Members of UroGen’s management team will host a live conference call and webcast today at 10:00 AM Eastern Time to review UroGen’s financial results and provide a general business update.

The live webcast can be accessed by visiting the Investors section of the Company’s website at http://investors.UroGen.com. Please connect at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast.

 UROGEN PHARMA LTD.SELECTED CONSOLIDATED BALANCE SHEETS(U.S. dollars in thousands)(Unaudited)            March 31, 2026 December 31, 2025Cash and cash equivalents and marketable securities $140,274  $120,456 Total assets $253,690  $200,455 Total liabilities $377,943  $305,929 Total shareholders' deficit $(124,253) $(105,474)  UROGEN PHARMA LTD.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(U.S. dollars in thousands, except share and per share data)(Unaudited)     Three months ended March 31,  2026   2025     Revenue$50,959  $20,254 Cost of revenue 4,139   2,330 Gross profit 46,820   17,924 Operating expenses:   Research and development expenses 15,597   19,871 Selling, general and administrative expenses 51,486   34,967 Total operating expenses 67,083   54,838 Operating loss (20,263)  (36,914)Financing on prepaid forward obligation (4,506)  (4,583)Interest expense on long-term debt (4,185)  (4,068)Interest and other income, net 608   2,114 Loss before income taxes$(28,346) $(43,451)Income tax benefit (expense) 4,772   (392)Net loss$(23,574) $(43,843)Net loss per ordinary share, basic and diluted$(0.47) $(0.92)Weighted average shares outstanding, basic and diluted 50,182,758   47,422,119      About ZUSDURI

ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, ZUSDURI is delivered directly into the bladder in an out-patient procedure by a trained healthcare professional using a urinary catheter to enable the treatment of tumors by non-surgical means.

APPROVED USE FOR ZUSDURI

ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove a tumor that did not work or is no longer working.

IMPORTANT SAFETY INFORMATION

You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI.

Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problems.are pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI.Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose.

Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose.
How will I receive ZUSDURI?

You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider’s instructions.If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.
After receiving ZUSDURI:

ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours.To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.
The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.

About JELMYTO

JELMYTO® (mitomycin) for pyelocalyceal solution is a mitomycin-containing reverse thermal gel containing 4 mg mitomycin per mL gel indicated for the treatment of adult patients with LG-UTUC. It is recommended for primary treatment of biopsy-proven LG-UTUC in patients deemed appropriate candidates for renal-sparing therapy. JELMYTO is a viscous liquid when cooled and becomes a semi-solid gel at body temperature. The drug slowly dissolves over four to six hours after instillation and is removed from the urinary tract by normal urine flow and voiding. It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube. The delivery system allows the initial liquid to coat and conform to the upper urinary tract anatomy. The eventual semisolid gel allows for chemoablative therapy to remain in the collecting system for four to six hours without immediately being diluted or washed away by urine flow.

APPROVED USE FOR JELMYTO

JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC).

IMPORTANT SAFETY INFORMATION

You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.

Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:

are pregnant or plan to become pregnant. JELMYTO can harm your unborn baby. You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with JELMYTO and for 6 months after the last dose. Males being treated with JELMYTO: If you have a female partner who is able to become pregnant, you should use effective birth control (contraception) during treatment with JELMYTO and for 3 months after the last dose.are breastfeeding or plan to breastfeed. It is not known if JELMYTO passes into your breast milk. Do not breastfeed during treatment with JELMYTO and for 1 week after the last dose.Tell your healthcare provider if you take water pills (diuretic).
How will I receive JELMYTO?Your healthcare provider will tell you to take a medicine called sodium bicarbonate before each JELMYTO treatment.You will receive your JELMYTO dose from your healthcare provider 1 time a week for 6 weeks. It is important that you receive all 6 doses of JELMYTO according to your healthcare provider’s instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. Your healthcare provider may recommend up to an additional 11 monthly doses.JELMYTO is given to your kidney through a tube called a catheter.During treatment with JELMYTO, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.
After receiving JELMYTO:JELMYTO may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 6 hours.To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.JELMYTO may cause serious side effects, including:Swelling and narrowing of the tube that carries urine from the kidney to the bladder (ureteric obstruction). If you develop swelling and narrowing, and to protect your kidney from damage, your healthcare provider may recommend the placement of a small plastic tube (stent) in the ureter to help the kidney drain. Tell your healthcare provider right away if you develop side pain or fever during treatment with JELMYTO.Bone marrow problems. JELMYTO can affect your bone marrow and can cause a decrease in your white blood cell, red blood cell, and platelet counts. Your healthcare provider will do blood tests prior to each treatment to check your blood cell counts during treatment with JELMYTO. Your healthcare provider may need to temporarily or permanently stop JELMYTO if you develop bone marrow problems during treatment with JELMYTO.The most common side effects of JELMYTO include: urinary tract infection, blood in your urine, side pain, nausea, trouble with urination, kidney problems, vomiting, tiredness, stomach (abdomen) pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first product to treat LG-UTUC and second product (mitomycin) for intravesical solution for adults with recurrent LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for ZUSDURI as a primary, non-surgical therapy for adults with recurrent LG-IR-NMIBC; ZUSDURI’s accelerating commercial uptake and growing rates of prescriber trial and adoption; the belief that growing clinical confidence in ZUSDURI will continue to drive commercial momentum and that the early launch trajectory provides validation of UroGen's commercial model; the belief in the significant commercial opportunity for ZUSDURI and UroGen’s ability to fully capitalize on it; the potential benefits and opportunities for UroGen’s product candidates, including UGN-103, UGN-104 and UGN-501; UroGen’s planned and ongoing clinical trials and IND-enabling studies and the timing for regulatory submissions and potential regulatory approvals for its product candidates, including the ongoing Phase 3 UTOPIA clinical trial of UGN-103, the ongoing Phase 3 clinical trial of UGN-104 and the IND-enabling studies of UGN-501, the planned NDA submission for UGN-103 and the potential regulatory approval thereof and the planned IND submission for UGN-501 and the potential Phase 1 trial thereof; the potential of UGN-501 to expand into additional tumor types beyond the genitourinary system; the expectation that UroGen’s next-generation medicines will enhance supply, improve manufacturing and preparation efficiencies and provide opportunity for lifecycle extensions; 2026 JELMYTO revenue and company operating expense guidance; the expected timeline of UroGen’s expanded debt facility with Pharmakon Advisors; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin and as a viable platform for local delivery of complex immunotherapies; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “can,” “continue,” “estimate,” “expect,” “may,” “on track,” “plan,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen’s products; risks related to UroGen’s and its licensors’ ability to protect their respective patents and other intellectual property, including that UroGen’s or its licensors’ pending patent applications may not be successful, and in such event, the duration of intellectual property protection would be more limited; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and ZUSDURI may not perform as expected; new data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market; the potential for payors to delay, limit or deny coverage for ZUSDURI; the data from the UTOPIA trial may not be sufficient to support approval of UGN-103; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, as well as in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q being filed with the SEC later today, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

Source: UroGen Pharma Ltd

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.

64.5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three MonthsFirst and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced a 36-month duration of response (DOR) of 64.5% (95% CI, 54.6% - 72.8%) by Kaplan-Meier estimate in patients who achieved a complete response (CR) at three months (79.6%) in the pivotal Phase 3 ENVISION trial of ZUSDURI™ (mitomycin) for intravesical solution. At a median follow-up of 35.5 months, the median DOR had not been reached. These data demonstrate that a substantial proportion of complete responders remained disease-free at three years, and durable outcomes were achieved without the need for maintenance therapy.

“This update from the pivotal ENVISION trial shows that many patients who achieve a complete response with ZUSDURI remain disease-free through three years,” said Sandip Prasad, M.D., M.Phil., Director of Genitourinary Surgical Oncology and Vice Chair of Urology at Morristown Medical Center/Atlantic Health System, NJ, and Principal Investigator of the ENVISION trial. “Among patients who achieved a complete response, the event rate over time has remained stable. Importantly, ZUSDURI’s durability was achieved without maintenance therapy, supporting a treatment approach that can provide lasting disease control while reducing ongoing treatment burden for patients.”

As a non-surgical, in-office treatment, ZUSDURI offers patients an opportunity to achieve meaningful disease- and treatment-free living without the burden of repeated TURBT procedures under general anesthesia. The current standard of care for LG-IR-NMIBC is transurethral resection of bladder tumor (TURBT), a surgical procedure typically performed under general anesthesia. Due to high recurrence rates following surgery, patients often undergo multiple TURBTs over their lifetime, leading to a cycle of repeat procedures that can impact quality of life and increase cumulative risk, particularly in older patients with comorbidities. An estimated 59,000 patients with LG-IR-NMIBC recur annually.

“The ENVISION 36-month DOR data reinforce ZUSDURI’s potential to shift the treatment paradigm for recurrent LG-IR-NMIBC,” said Mark Schoenberg, M.D., Chief Medical Officer, UroGen. “By delivering durable responses without maintenance therapy, ZUSDURI provides an opportunity to move beyond the cycle of repeated surgical interventions and toward a more durable, lower-burden treatment approach over time.”

The most common (≥ 10%) adverse reactions (ARs), including laboratory abnormalities, that occurred in patients were dysuria, increased potassium, increased creatinine, decreased hemoglobin, increased eosinophils, increased aspartate aminotransferase, increased alanine aminotransferase, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria. ARs were mainly mild to moderate. Serious ARs occurred in 12% of patients, including urinary retention (0.8%) and urethral stenosis (0.4%).

About ZUSDURI

ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel® technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means.

About Non-Muscle Invasive Bladder Cancer (NMIBC)
LG-IR-NMIBC affects around 82,000 people in the United States every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include TURBT as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about non-muscle invasive bladder cancer at www.BladderCancerAnswers.com.

About ENVISION
The Phase 3 ENVISION trial is a single-arm, multinational, multicenter pivotal study evaluating the efficacy and safety of ZUSDURI (mitomycin) for intravesical solution as a chemoablative therapy in adult patients with recurrent LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of ZUSDURI. The primary endpoint evaluated the CR rate three months after the first instillation, and the key secondary endpoint evaluates durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product, ZUSDURI (mitomycin) for intravesical solution for adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.

APPROVED USE FOR ZUSDURI
ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working.
IMPORTANT SAFETY INFORMATION

You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI.

Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problemsare pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI.
Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose.

Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose.
How will I receive ZUSDURI?

You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider’s instructions.If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.
After receiving ZUSDURI:

ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours.To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.
The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.

Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential benefits of ZUSDURI, including as an outpatient treatment option, its potential to provide durable CRs without maintenance therapy and clinically meaningful disease- and recurrence-free intervals; the potential of ZUSDURI to shift the treatment paradigm and provide a compelling non-surgical alternative to TURBT for the treatment of recurrent LG-IR-NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the ongoing Phase 3 ENVISION trial; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “can,” “estimate,” “likely,” “may,” “potential,” “will” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: clinical results may not be indicative of results that may be observed in the future, including in larger populations; potential safety and other complications related to UroGen’s products; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and ZUSDURI may not perform as expected; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q being filed with the SEC on May 6, 2026, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially   and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
[email protected] 
609-460-3588 ext. 1093

MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1, 97.9) durability of response (DOR) at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The six-month results from UTOPIA are generally consistent with the 91.9% (95% CI: 86.9, 95.0) six-month DOR observed with ZUSDURI™ (mitomycin) for intravesical therapy in its pivotal ENVISION trial. ZUSDURI is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for adult patients with recurrent LG-IR-NMIBC.

Based on the consistency of UTOPIA data with the results of the ENVISION trial studying ZUSDURI in patients meeting the same eligibility criteria and alignment with the FDA, UroGen remains on track to submit a New Drug Application (NDA) for UGN-103 in the third quarter of 2026.

“The durability of response observed at six months with UGN-103 in the UTOPIA trial is generally consistent with that observed in the pivotal ENVISION trial of ZUSDURI, and highlights the potential to further advance care for adult patients with recurrent LG-IR-NMIBC,” said Abishek Srivastava, MD, Urologic Oncologist at Atlantic Urology Clinics, Myrtle Beach, SC, START Center for Cancer Research, Carolinas and lead investigator of the UTOPIA trial. “UGN-103 builds on a proven therapeutic approach with meaningful innovations that could help enhance how we deliver this therapy in clinical practice.”

UGN-103 is designed to build on the clinical and commercial foundation of ZUSDURI. The benefits of UGN-103 include a more streamlined manufacturing process and simplified reconstitution, while preserving the innovative and proven RTGel® technology that enables sustained drug exposure at tumor sites in the bladder.

“These clinical data reinforce the potential of UGN-103 to become a new standard of care for adult patients with recurrent LG-IR-NMIBC,” said Liz Barrett, President and Chief Executive Officer of UroGen. “With FDA alignment on our regulatory path, we are advancing with urgency toward NDA submission. We believe UGN-103 represents a significant opportunity to build on our leadership in uro-oncology, expand our commercial portfolio, and drive long-term growth.”

UroGen holds U.S. patents covering the combination of its proprietary RTGel technology with medac’s licensed lyophilized mitomycin formulation, as well as the use of UGN-103 in LG-IR-NMIBC, with intellectual property protection expected to extend into December 2041.

About UTOPIA

The UTOPIA trial is a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in 99 patients across global sites. Enrolled patients received 75 mg of UGN-103 via intravesical instillation in an outpatient setting once weekly for six weeks. The primary endpoint is CR rate at three months, with responders entering a follow-up phase of up to 12 months to assess DOR. For more information on the UTOPIA study, please visit https://clinicaltrials.gov/study/NCT06331299.

About UGN-103
In January 2024, UroGen entered into a licensing and supply agreement with medac to develop UGN-103 for recurrent LG-IR-NMIBC. UGN-103 is designed to reinforce and extend the clinical and commercial profile of ZUSDURI, the first and only FDA-approved treatment for adults with recurrent LG-IR-NMIBC. The program maintains UroGen’s innovative and proven RTGel technology, enabling sustained mitomycin exposure in the bladder, while incorporating next-generation enhancements, including a more streamlined manufacturing process and simplified reconstitution to support improved ease of use in clinical practice. UroGen holds U.S. patents covering the combination of its proprietary RTGel technology with medac’s licensed lyophilized mitomycin formulation, as well as the use of UGN-103 in LG-IR-NMIBC, with intellectual property protection expected to extend into December 2041.

About ZUSDURI

ZUSDURI (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin approved for the treatment of adults with recurrent LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel technology (a sustained release, hydrogel-based formulation), ZUSDURI is delivered directly into the bladder by a trained healthcare professional using a urinary catheter in an outpatient setting, thereby enabling the treatment of tumors by non-surgical means.

About Non-Muscle Invasive Bladder Cancer (NMIBC)
LG-IR-NMIBC affects around 82,000 people in the United States every year and of those, an estimated 59,000 are recurrent. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include transurethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence, and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures. Learn more about NMIBC at www.BladderCancerAnswers.com.

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product, ZUSDURI (mitomycin) for intravesical solution, is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.

About medac CDMO
The belief that health is humanity’s most valuable resource drives medac group. Since 1970, the mission of medac has been to improve patients’ quality of life worldwide by making the best medical treatments available. Since 2000, medac has been dedicated to improving patient outcomes globally by supporting pharmaceutical companies in bringing the best medical treatments to market. As a trusted Contract Development and Manufacturing Organization (CDMO), headquartered in Germany, medac CDMO is specialised in providing customised, high-quality services to customers and worldwide markets.

With a team of over 2,000 highly skilled professionals, medac CDMO offers comprehensive solutions tailored to the needs of clients worldwide. The cutting-edge facilities of medac group in Germany and the Czech Republic are equipped with the latest technologies to ensure precision, efficiency and compliance with the most stringent industry standards. From early-stage development to large-scale commercial production, medac CDMO is committed to foresight, progress, reliability and creative thinking which makes them a solution ahead.

The deep expertise, commitment to quality and flexible manufacturing capabilities enable medac CDMO to serve as a trusted partner for pharmaceutical and biotech companies looking to scale their operations and bring life-changing treatments to patients around the globe.

For more information, please visit www.medac-cdmo.com.

APPROVED USE FOR ZUSDURI
ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after previously receiving bladder surgery to remove tumor that did not work or is no longer working.

IMPORTANT SAFETY INFORMATION

You should not receive ZUSDURI if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI.

Before receiving ZUSDURI, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problemsare pregnant or plan to become pregnant. ZUSDURI can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI.
Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI and for 6 months after the last dose.

Males being treated with ZUSDURI: You should use effective birth control (contraception) during treatment with ZUSDURI and for 3 months after the last dose.

are breastfeeding or plan to breastfeed. It is not known if ZUSDURI passes into your breast milk. Do not breastfeed during treatment with ZUSDURI and for 1 week after the last dose.
How will I receive ZUSDURI?

You will receive your ZUSDURI dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI according to your healthcare provider’s instructions.If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.During treatment with ZUSDURI, your healthcare provider may tell you to take additional medicines or change how you take your current medicines.
After receiving ZUSDURI:

ZUSDURI may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours.To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water.Clothing that comes in contact with urine should be washed right away and washed separately from other clothing.
The most common side effects of ZUSDURI include: increased blood creatinine levels, increased blood potassium levels, trouble with urination, decreased red blood cell counts, increase in certain blood liver tests, increased or decreased white blood cell counts, urinary tract infection, and blood in your urine.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please see ZUSDURI Full Prescribing Information, including the Patient Information, for additional information.

Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for the Phase 3 UTOPIA trial to support an NDA submission for UGN-103 and the planned timing thereof; the potential path toward approval of UGN-103 and potential approval thereof; the potential of UGN-103 to advance care for and provide benefits to adult patients with recurrent LG-IR-NMIBC and become a new standard of care; the potential of UGN-103 to build on UroGen’s leadership in uro-oncology, expand its commercial portfolio, and drive long-term growth; the potential benefits of UGN-103 as compared to ZUSDURI, including its streamlined manufacturing and reconstitution processes and expected intellectual property protection; the expected duration of intellectual property protection for UGN-103; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs other than mitomycin; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “believe,” “can,” “estimated,” “expect,” “may,” “plan,” “potential,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: preliminary clinical results may not be indicative of results that may be observed in the future; potential safety and other complications related to UroGen’s products and product candidates; risks related to our and our licensors’ ability to protect our respective patents and other intellectual property, including the fact that UroGen’s or our licensors’ pending patent applications may not be successful, and in such event, the duration of intellectual property protection would be more limited; the ability to maintain regulatory approval; complications associated with commercialization activities; labeling limitations; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s products and product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology and UroGen’s products and product candidates may not perform as expected; the data from the UTOPIA trial may not be sufficient to support approval of UGN-103; UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology; and the impacts of general macroeconomic and geopolitical conditions on UroGen’s business and financial position. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 6, 2026, the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA CONTACT:
Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

PRINCETON, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference to take place on June 8-10, 2026.

Goldman Sachs 47th Annual Global Healthcare Conference

Date / Time:June 10, 2026, at 8:40 AM ETFormat:Fireside chat and 1x1 investor meetingsLocation:Miami Beach, FLWebcast Link:here
The webcast from the conference will also be available on UroGen’s corporate website, under Events & Presentations. A replay will be available for approximately 90 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product is approved for adult patients with recurrent LG-IR-NMIBC. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on X, @UroGenPharma.

INVESTORS:

Vincent Perrone
Senior Director, Investor Relations
[email protected]
609-460-3588 ext. 1093

MEDIA:

Cindy Romano
Director, Corporate Communications
[email protected]
609-460-3566 ext. 1083

PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 21 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution and ZUSDURITM (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.

Up to 102,700 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X, @UroGenPharma.

JELMYTO®, RTGel®, ZUSDURI™ and UroGen® are registered trademarks of UroGen Pharma Ltd.

INVESTOR CONTACT:
Vincent Perrone
[email protected]
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
[email protected]
(609) 460-3566 Ext. 1083

ACNT is now a pure-play specialty chemicals company. They've replaced their mixed tubing-and-chemicals operations with a leaner industrial specialty chemicals focus. 2025 was mixed as revenues declined, but gross profit, gross margin, and adjusted EBITDA improved materially. In my view, this suggests that ACNT's leaner business model is strengthening despite the expected initial transition friction.

Posted by Defense World Staff on Apr 17th, 2026

Ascent Industries Co. (NASDAQ:ACNT – Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 338,424 shares, a growth of 19.5% from the March 15th total of 283,226 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average daily volume of 138,633 shares, the short-interest ratio is currently 2.4 days.

Wall Street Analysts Forecast Growth Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Ascent Industries in a research report on Tuesday. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold”.

View Our Latest Stock Report on ACNT

Ascent Industries Price Performance Shares of NASDAQ:ACNT opened at $13.92 on Friday. The company has a quick ratio of 6.01, a current ratio of 6.72 and a debt-to-equity ratio of 0.01. Ascent Industries has a fifty-two week low of $11.46 and a fifty-two week high of $17.92. The firm has a 50-day simple moving average of $14.65 and a 200 day simple moving average of $14.54. The company has a market cap of $128.62 million, a PE ratio of 126.56 and a beta of 0.55.

Ascent Industries (NASDAQ:ACNT – Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.27). Ascent Industries had a net margin of 1.06% and a negative return on equity of 2.89%. The business had revenue of $18.76 million for the quarter, compared to the consensus estimate of $48.90 million.

Ascent Industries declared that its board has approved a stock repurchase program on Thursday, December 18th that permits the company to repurchase $2.00 million in shares. This repurchase authorization permits the company to reacquire up to 1.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Insider Activity In other Ascent Industries news, CEO John Bryan Kitchen acquired 7,595 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was acquired at an average price of $12.98 per share, with a total value of $98,583.10. Following the transaction, the chief executive officer directly owned 79,985 shares in the company, valued at approximately $1,038,205.30. This represents a 10.49% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Anthony X. Pan acquired 3,400 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average cost of $13.30 per share, with a total value of $45,220.00. Following the transaction, the vice president owned 20,651 shares in the company, valued at approximately $274,658.30. The trade was a 19.71% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 9.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of ACNT. Goldman Sachs Group Inc. bought a new position in Ascent Industries in the 1st quarter worth about $227,000. Empowered Funds LLC grew its position in Ascent Industries by 6.5% in the 1st quarter. Empowered Funds LLC now owns 47,620 shares of the company’s stock worth $603,000 after purchasing an additional 2,927 shares during the last quarter. Jane Street Group LLC bought a new position in Ascent Industries in the 1st quarter worth about $269,000. Geode Capital Management LLC grew its position in Ascent Industries by 91.9% in the 2nd quarter. Geode Capital Management LLC now owns 194,433 shares of the company’s stock worth $2,452,000 after purchasing an additional 93,125 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Ascent Industries by 121,970.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 12,207 shares of the company’s stock worth $154,000 after purchasing an additional 12,197 shares during the last quarter. Institutional investors own 26.05% of the company’s stock.

About Ascent Industries (Get Free Report)

Ascent Industries Co an industrials company, produces and distributes stainless steel pipe and tube and specialty chemicals in the United States and internationally. The company operates through two segments, Tubular Products and Specialty Chemicals. It manufactures welded pipes and tubes, primarily from stainless steel, duplex, and nickel alloys; and ornamental stainless steel tubes for automotive, commercial transportation, marine, food services, construction, furniture, healthcare, and other industries.

Further Reading Five stocks we like better than Ascent Industries Receive News & Ratings for Ascent Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascent Industries and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAureus Greenway Holdings Inc. (NASDAQ:AGH) Sees Large Decline in Short Interest

NEXT HEADLINE »Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 21.7% in March

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Ascent Industries Co. (Nasdaq: ACNT) (“Ascent” or the “Company”), a specialty chemicals platform delivering differentiated, performance-driven chemical solutions, is reporting its results for the first quarter ended March 31, 2026. First Quarter 2026 Summary1 (in millions, except per share and margin) Q1 2026 Q1 2025 Change Net Sales $19.4 $17.8 9.0% Gross Profit $2.8 $3.1 (8.3)% Gross Profit Margin 14.5% 17.2% -272bps Net Loss $(2.0) $(2.2) (9.0)% Diluted Los.

Ascent Industries Co. (ACNT) Q1 2026 Earnings Call Transcript

RESTON, Va.--(BUSINESS WIRE)--Comstock Holding Companies, Inc. (Nasdaq: CHCI) (“Comstock”), a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region, today highlighted a feature profile on Dwight Schar published by HousingWire that recognizes his enduring impact on the homebuilding industry and continued influence on Comstock's long-term strategy. The online feature provides a comprehensive look at Mr. Schar's career, including.

RESTON, Va.--(BUSINESS WIRE)--Comstock Acquires Woodland Pointe, Secures Full-Campus Lease with Peraton.

VIRGINIA CITY, Nev., April 30, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE American: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company's CEO, Corrado De Gasperis, and CFO, Judd Merrill will be providing an overview of our first quarter 2026 financial results and current business updates on Thursday, May 7, 2026, at 4:30pm ET. We invite all investors and other interested parties to register for the webinar at the link below.

Comstock reported a $223 million free cash flow deficit in Q1 2026, including the impact of $55 million in midstream capex. While benchmark natural gas prices averaged near $5, Comstock realized $3.46 per Mcfe for its production during the quarter. Comstock had significant realized hedging losses in Q1 2026 and also dealt with temporarily wider regional differentials.

Comstock Resources (CRK) reported capital outspending and a production decline, triggering a 13% stock drop amid market skepticism. CRK is investing in delineating new Western Haynesville acreage. Management expects well delays that are part of the legacy Haynesville acreage to resolve in Q2.

Comstock Inc. (LODE - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +20.00%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.24, delivering a surprise of -33.33%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

COMSTOCK INC, which belongs to the Zacks Waste Removal Services industry, posted revenues of $0.31 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 29.56%. This compares to year-ago revenues of $0.79 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

COMSTOCK INC shares have lost about 13% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for COMSTOCK INC?While COMSTOCK INC has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for COMSTOCK INC was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.13 on $4.83 million in revenues for the coming quarter and -$0.41 on $22.96 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Waste Removal Services is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Algorhythm Holdings, Inc. (RIME - Free Report) , another stock in the broader Zacks Business Services sector, has yet to report results for the quarter ended March 2026.

This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of +84.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Algorhythm Holdings, Inc.'s revenues are expected to be $2 million, up 0.5% from the year-ago quarter.

2 hours ago

T3 Companies LLC Takes Position in Tesla, Inc. $TSLAT3 Companies LLC bought a new stake in shares of Tesla, Inc. (NASDAQ:TSLA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,870 shares of the electric vehicle producer's stock, valued at approximately $841,000

NASDAQ:TSLA

Read T3 Companies LLC Takes Position in Tesla, Inc. $TSLA

2 hours ago

T3 Companies LLC Buys Shares of 15,096 lululemon athletica inc. $LULUMarketBeat

T3 Companies LLC purchased a new stake in lululemon athletica inc. (NASDAQ:LULU - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 15,096 shares of the apparel retailer's

NASDAQ:LULU

Read T3 Companies LLC Buys Shares of 15,096 lululemon athletica inc. $LULU

2 hours ago

Renaissance Group LLC Purchases New Position in Nextpower Inc. $NXTMarketBeat

Renaissance Group LLC purchased a new stake in shares of Nextpower Inc. (NASDAQ:NXT - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 73,688 shares of the company's stock, valued at approximately $6,419,000. Other institutional

NASDAQ:NXT

Read Renaissance Group LLC Purchases New Position in Nextpower Inc. $NXT

2 hours ago

Credo Technology Group Holding Ltd. $CRDO Stock Holdings Decreased by Renaissance Group LLCMarketBeat

Renaissance Group LLC lowered its position in shares of Credo Technology Group Holding Ltd. (NASDAQ:CRDO - Free Report) by 27.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,007 shares of the company's s

NASDAQ:CRDO

Read Credo Technology Group Holding Ltd. $CRDO Stock Holdings Decreased by Renaissance Group LLC

2 hours ago

Renaissance Group LLC Has $9.54 Million Stock Position in Flex Ltd. $FLEXMarketBeat

Renaissance Group LLC lessened its position in shares of Flex Ltd. (NASDAQ:FLEX - Free Report) by 9.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,814 shares of the technology company's stock after selling 16

NASDAQ:FLEX

Read Renaissance Group LLC Has $9.54 Million Stock Position in Flex Ltd. $FLEX

2 hours ago

Renaissance Group LLC Lowers Stake in Millicom International Cellular SA $TIGOMarketBeat

Renaissance Group LLC cut its holdings in Millicom International Cellular SA (NASDAQ:TIGO - Free Report) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 180,034 shares of the technology company's stock after selling 21,873

NASDAQ:TIGO

Read Renaissance Group LLC Lowers Stake in Millicom International Cellular SA $TIGO

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 323

-

Signature event series returns to celebrate summer with free concerts, movies, and more

RESTON, Va.--(BUSINESS WIRE)--Comstock Holding Companies, Inc. (Nasdaq: CHCI) (“Comstock”), a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region, today announced the full lineup for the Summerbration 2026 concert and event series at Loudoun Station. The events, which kick off in June and run through October, include signature concerts, outdoor movies, car shows, weekly wellness classes, and more.

“We’re thrilled to welcome the community back to Loudoun Station for another Summerbration season,” said Tracy Schar, Chief Marketing Officer at Comstock.

Share Headlining the Summerbration 2026 series will once again be the highly anticipated 80’s Mayhem event featuring The Legwarmers on Saturday, August 29. Guests are invited to enjoy an evening of live music, themed entertainment, a costume contest, photo opportunities, and more.

Venardos Circus makes their return to Loudoun Station this fall, bringing its unique Broadway-style blend of theatrical storytelling with classic circus entertainment. Running from September 14 through October 4, the experience is expected to draw theater lovers, families, and nostalgic circus fans alike to Loudoun Station District Park. Separate tickets are required for admission and additional details are available at venardoscircus.com/tickets.

Summerbration 2026 will also feature All-American Movie Magic & More, a weekly outdoor movie series held on Sundays in Loudoun Station District Park. The family-focused lineup pairs beloved films with themed activities and giveaways, including karaoke, inflatable games, glow sticks, hula hoops, meet-and-greets, pet adoption opportunities, and interactive experiences inspired by each movie. Featured films include Rudy, Back to the Future, Big, The Sandlot, Minions, Willy Wonka and the Chocolate Factory, School of Rock, Pitch Perfect, and many more crowd favorites.

Automotive enthusiasts can also enjoy a series of car shows hosted throughout the summer by the DC Car Community. The events will showcase vehicles and make Loudoun Station the place for car lovers from across the entire DMV region to gather.

“We’re thrilled to welcome the community back to Loudoun Station for another Summerbration season,” said Tracy Schar, Chief Marketing Officer at Comstock. “From live entertainment and movies to wellness and community events, Summerbration is all about creating experiences that bring people together and give families something to look forward to all summer long.”

Rounding out the Summerbration 2026 lineup are complimentary weekly wellness classes, including Yoga in the Park on Mondays and Zumba in the Park on Tuesdays, and Pop-Up Zumba with Rochi B Fitness on Saturday, June 27 and Sunday, September 20. Also returning is the crowd-favorite Silent Dance Party on July 25.

All Summerbration 2026 events are free and open to the public, unless otherwise noted. Loudoun Station is conveniently located adjacent to the Ashburn Station on Metro's Silver Line. Attendees who drive may enjoy up to three hours of complimentary parking in the 9-story Metro Garage, courtesy of ParkX Management.

For a full listing of events and further information, please visit the Summerbration 2026 website.

About Comstock

Founded in 1985, Comstock is a leading asset manager, developer, and operator of mixed-use and transit-oriented properties in the Washington, D.C. region. With a managed portfolio comprising approximately 10 million square feet at full build-out and including stabilized and development assets strategically located at key Metro stations, Comstock is at the forefront of the urban transformation taking place in the fastest-growing segments of one of the nation’s best real estate markets. Comstock’s developments include some of the largest and most prominent mixed-use and transit-oriented projects in the mid-Atlantic region, as well as multiple large-scale public-private partnership developments. For more information, please visit Comstock.com.

More News From Comstock Holding Companies, Inc.

Back to Newsroom

Shares of Comstock Holding Companies, Inc. (CHCI - Free Report) have declined 7.3% since the company reported results for the quarter ended March 31, 2026, underperforming the S&P 500 index’s 1.4% decline during the same period. Over the past month, the stock has fallen 8.8%, compared with a 3.7% gain for the broader benchmark index.

Comstock reported first-quarter 2026 earnings per share of 19 cents, which rose from 15 cents a year earlier. 

Revenue of $17.4 million denoted a 38% rise from $12.6 million in the year-ago quarter, while net income rose 25% to $2 million from $1.6 million. Adjusted EBITDA climbed 6% year over year to $2.2 million. The company also expanded its managed portfolio to 100 assets from 76 in the prior-year period. 

Portfolio Growth and Leasing ActivityComstock continued to benefit from growth in its asset management and property management operations during the quarter. Stabilized commercial assets were 93% leased as of March 31, with seven commercial leases signed during the quarter covering about 38,000 square feet of office and retail space.

Residential assets were 94% leased, with 150 units leased during the quarter.
The company highlighted strong demand for trophy office space at Reston Station. 96% of the 1.3 million square feet of trophy-class office space across Reston Station’s five office towers is currently leased or reserved.

Comstock’s ParkX subsidiary also posted notable growth, with revenue increasing 106% from the prior year. The business secured 13 new contracts during the quarter, including five new third-party agreements.

Management Commentary and Revenue DriversChairman and Chief Executive Officer Christopher Clemente attributed the quarter’s performance to the company’s focus on strategically located mixed-use and transit-oriented assets. He said expanding assets under management have helped generate diversified recurring fee-based revenue streams while supporting long-term growth.

The company also emphasized the benefits of its debt-free balance sheet and fee-based business model. Management noted that long-term asset management agreements and vertically integrated operating subsidiaries provide recurring revenue streams and downside protection.

Adjusted EBITDA growth was primarily driven by increases in recurring fee-based revenue from Comstock’s operating property management subsidiaries and higher asset management fees tied to portfolio expansion.

Comstock also pointed to transaction-related revenue generated by acquisitions completed through its Institutional Venture Platform (“IVP”), which contributed to development pipeline growth and additional fee-based revenue opportunities.

Expansion Initiatives and Development PipelineThe company continued to expand its development and investment platforms during the quarter. In March 2026, Comstock acquired The Reed, a 417-unit multifamily property in Rockville, Md., through its IVP platform. Early in the second quarter, it also acquired Woodland Pointe, a fully leased office complex in Herndon, Va., which includes an existing 185,000-square-foot office building and a future build-to-suit office project.

Comstock also recently launched a Data Center Platform focused on joint venture opportunities tied to data center development. Management said the initiative is intended to capitalize on growing demand for data center capacity and create additional fee-based revenue opportunities.

In addition, the company expanded into mall management through its assumption of management responsibilities for Dulles Town Center in Virginia beginning May 1. The assignment includes property management, leasing, tenant relations and redevelopment evaluation services.

Other DevelopmentsComstock highlighted several operational milestones during the quarter, including a record-setting $10.3 million condominium sale at JW Marriott Residences Reston Station, surpassing the previous Virginia condominium sales record of $6 million.

The company also continues to advance major projects at The Row at Reston Station. BLVD Haley, a 419-unit luxury residential tower, remains on track for full delivery by the second quarter of 2026, while Ebbitt House — the first expansion of Washington, D.C.’s Old Ebbitt Grill — is also nearing opening.

June 10, 2026 16:45 ET  | Source: Comstock Inc.

VIRGINIA CITY, Nev., June 10, 2026 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock,” “our” and the “Company”), today announced that Judd B. Merrill, Chief Financial Officer, will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at the Bellagio Resort & Hotel.  Visit us in Booth #301.

To access the live presentation, please use the following information:

Planet MicroCap Las Vegas 2026 Powered by MicroCapClub

Date: Wednesday, June 17, 2026
Time: 8:30-9:00 AM PST
Webcast: Link here

CEO Interview: Link here

If you would like to book 1x1 investor meetings with Comstock Inc., and to attend the Planet MicroCap Las Vegas 2026, please make sure you are registered here: Register

1x1 meetings will be scheduled and conducted in person at the conference venue: Bellagio Resort & Hotel in Las Vegas, NV.

The Planet MicroCap Las Vegas 2026 website is available here: Planet Microcap

If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda” here: Agenda

About Planet MicroCap

Planet Microcap hosts the highest quality microcap in-person events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow. For more information about Planet MicroCap, please visit: https://planetmicrocap.com/

About Planet MicroCapClub

MicroCapClub is an exclusive forum for experienced microcap investors to share and discuss microcap companies (sub $1 billion market cap) trading on global markets. Since 2011, our members have profiled 1500+ microcap companies, 300+ have turned into multi-baggers. Investors can join our community by applying to become a member or subscribing to gain instant access. For more information, visit https://microcapclub.com/

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
[email protected]

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
[email protected]

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “forecast,” “seek,” “target,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: expectations regarding the completion of the proposed securities offering, future market conditions; future explorations or acquisitions, divestitures, spin-offs or similar distribution transactions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: sales of, and demand for, our products, services, and/or properties; industry market conditions, including the volatility and uncertainty of commodity prices; the speculative nature, costs, regulatory requirements, and hazards of natural waste resource identification, exploration, development, availability, recycling, extraction, processing, and refining activities, including operational or technical difficulties, and risks of diminishing quantities or insufficiency of grades of qualified resources;; changes in our planning, exploration, research and development, production, and operating activities; research and development, exploration, production, operating, and other variable and fixed costs; throughput rates, margins, earnings, debt levels, contingencies, taxes, capital expenditures, net cash flows, and growth; restructuring activities, including the nature and timing of restructuring charges and the impact thereof; employment and contributions of personnel, including our reliance on key management personnel; the costs and risks associated with developing new technologies; our ability to commercialize existing and new technologies; the impact of new, emerging, and competing technologies on our business; the possibility of one or more of the markets in which we compete being impacted by political, legal, and regulatory changes, or other external factors over which we have little or no control; the effects of mergers, consolidations, and unexpected announcements or developments from others; the impact of laws and regulations, including permitting and remediation requirements and costs; changes in or elimination of laws, regulations, tariffs, trade, or other controls or enforcement practices, including the potential that we may not be able to comply with applicable regulations; changes in generally accepted accounting principles; adverse effects of climate changes, natural disasters, and health epidemics, such as the COVID-19 outbreak; global economic and market uncertainties, changes in monetary or fiscal policies or regulations, the impact of terrorism and geopolitical events, volatility in commodity and/or other market prices, and interruptions in delivery of critical supplies, equipment and/or raw materials; assertion of claims, lawsuits, and proceedings against us; potential inability to satisfy debt and lease obligations, including because of limitations and restrictions contained in the instruments and agreements governing our indebtedness; our ability to raise additional capital and secure additional financing; interruptions in our production capabilities due to equipment failures or capital constraints; potential dilution from stock issuances, recapitalization, and balance sheet restructuring activities; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to maintain the listing of our securities on any securities exchange or market; and our ability to implement additional financial and management controls, reporting systems and procedures and comply with Section 404 of the Sarbanes-Oxley Act, as amended. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Agnico Eagle Mines Ltd (TSX:AEM) has struck a series of deals worth about $3 billion to build a regional gold mining hub in northern Finland, sending shares of takeover targets sharply higher.

The Canadian miner said it will acquire Rupert Resources Ltd (TSE:RUP) in a share-based transaction valued at about C$2.9 billion, alongside a C$481 million cash purchase of Aurion Resources (TSX-V:AU) and a $325 million deal to buy B2Gold Corp. (TSX:BTO)’s 70% stake in Fingold Ventures.

The transactions are aimed at consolidating assets in Finland’s Central Lapland Greenstone Belt, including the Ikkari gold project located about 50 km from Agnico’s Kittila mine, its largest European operation.

Shares of Aurion jumped about 44% in Canada, while Rupert surged roughly 65% following the announcement.

Jefferies analysts said the combined transactions, valued at roughly $2.8 billion, are expected to be modestly accretive, estimating about a 2% increase to net asset value per share, helped by potential synergies of up to C$500 million.

The Rupert acquisition implies a valuation of about 0.54 times net asset value and includes contingent cash payments tied to project milestones. The deal carries a premium of about 67% to Rupert’s last closing price and is expected to close in early third quarter 2026, alongside the Aurion transaction.

The Fingold Ventures purchase is set to close earlier, in April 2026, and will give Agnico full control of the project, as Aurion owns the remaining 30% stake.

As part of the agreement, B2Gold will also enter a collaboration arrangement with Agnico focused on knowledge sharing in Nunavut, where B2Gold is advancing its Goose project.

Agnico said the deals would help establish Finland as a core production region, with output potentially rising to about 500,000 ounces per year, more than double expected 2026 production from Kittila.

Jefferies said the move underscores Agnico’s strategy of building regional platforms to unlock operational synergies, rather than pursuing geographically dispersed acquisitions.

“We favor regional consolidation, as it leads to real operational synergies versus only G&A synergies,” analysts wrote.

“In this case, there are opportunities for AEM to extend the Ikkari open pit onto the Fingold Ventures area, i.e., removing the property boundary, and the company sees up to C$500 million in operating, development, and construction synergies.”